ZLDPF News and Press, Zealand Pharma A/S Ord

Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...

Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...

Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...

2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...

2024-06-21 08:20:43 ET More on Zealand Pharma Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Zealand, Boehringer liver disease drug survodutide shows fibrosis improvement Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide ...

Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Body weight reductions of up to a mean of 8.6% with high dose petrelintide after...

2024-06-07 10:21:55 ET More on Zealand Pharma Zealand Pharma: Survodutide Has Potential Beyond Obesity Treatment Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Hist...

Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis News builds on previously announced primary e...

Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark, June 6, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today announced that an embargoed ...